Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice
Article 2018 en
Authors
ET
Evangelos Terpos
EK
Eirini Katodritou
JR
Javier de la Rubia
Abstract
1 min read
These prospective real-world data demonstrate the effectiveness and safety of bortezomib-based therapy for RRMM and confirm high response rates and long OS for this population.
Cyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, Evangelos Terpos, Eirini Katodritou, Vânia Hungria, Hadewijch De Samblanx, Anne‐Marie Stoppa, Jesper Aagesen, Deniz Sargın, Anastasia Sioni, Andrew Belch, Joris Diels, Robert A. Olie, Don Robinson, Anna Potamianou, Helgi van de Velde, Michel Delforge
Meletios A Dimopoulos, Joseph Mıkhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl‐Goldstein, Paul G. Richardson
Lisa Leypoldt, Maria Gavriatopoulou, Britta Besemer, H. Salwender, Marc‐Steffen Raab, Axel Nogai, Cyrus Khandanpour, V. Runde, Manola Zago, Peter Martus, H. Goldschmidt, Carsten Bokemeyer, Meletios A Dimopoulos, Katja Weisel
Discussion(0)
No comments yet. Be the first to comment.